what happens when you take too much tirzepatide to Expect Before and After Tirzepatide Dosing - A Patient

Several indirect mechanisms may explain why some individuals experience increased thirst while taking GLP-1 medications, even though thirst is not a direct pharmacologic effect of these agents

Tirzepatide is a dual GIP/GLP-1 receptor agonist administered once weekly via subcutaneous injection for weight management and type 2 diabetes

We invite you to experience the Timeless RX difference

Instead, its designed to: Be introduced at low doses Increase gradually to reduce side effects Support steady, sustainable changes This approach helps the body adapt and improves long-term outcomes

None of this is arbitrary

Various drugs are used to treat RLS, with dopamine agonists (DAs) being the first-line treatment